摘要:
The invention relates to a process for the production of 4-(17α-methyl-substituted 3-oxoestra-4,9-dien-11β-yl)benzaldehyde-(1E or 1Z)-oximes of general formula (I), in which R1 is a hydrogen atom, a C1-6-alkyl radical or a CnF2n+1 radical, whereby n is 1, 2 or 3, R2 is a C1-4-alkyl radical, X is an OH group in E- or Z-position, and Y is an OC1-6-alkyl group, an SC1-6-alkyl group or an OCH2CnF2+1 group, whereby n is 1, 2 or 3, which provides the target compounds of formula (I) with a high yield and good selectivity
摘要:
The invention relates to a method for the production of 4-(17α substituted 3-oxoestra-4,9-dien-11β-yl)benzaldehyd-(1E or 1Z)-oximes of general formula (I), where R1═H, C1-6 alkyl or a CnF2n+1 group; R2═C1-4 alkyl, X=E- or Z-OH; and Y═O—C1-6 alkyl, S—C1-6 alkyl or O—CH2CnF2n+1, where n=1, 2 or 3, which produces the target compounds of formula (I) with high yield and selectivity.
摘要翻译:本发明涉及一种制备通式(I)的4-(17α取代的3-氧代雌-4,9-二烯-11β-基)苯甲醛 - (1E或1Z) - 肟的方法, 1-H,C 1-6烷基或C n H 2n + 1 + 1个基团; R 2 -C 1-4烷基,X = E-或Z-OH; 和YOC 1-6烷基,SC 1-6烷基或O-CH 2 C n N > 2n + 1,其中n = 1,2或3,其以高产率和选择性产生式(I)的目标化合物。
摘要:
The present invention discloses the use of ERβ-selective ligands for production of medicaments for regulating fertility without additional use of a progestin. ERβ-agonists are used for treatment of infertility and ERβ-antagonists for contraception.
摘要:
The present invention discloses the use of ER&bgr;-selective ligands for production of medicaments for regulating fertility without additional use of a progestin. ER&bgr;-agonists are used for treatment of infertility and ER&bgr;-antagonists for contraception.
摘要:
The invention is directed to novel steroid intermediate products of general formula I ##STR1## The steroid intermediate products which can be isolated according to the invention are suitable for the synthesis of 13-ethyl-11-methylene-18,19-bisnor-17.alpha.-pregn-4-en-20-in-17-ol (desogestrel). Further, processes for producing the steroid intermediate products of general formula I are described. The olefination of the 11-oxo steroids is carried out under the influence of ultrasound.
摘要:
The present patent application relates to 11β-benzaldoxime derivatives of D-homooestra-4,9-dien-3-ones of formula I: wherein R1 is a hydrogen atom or a C1-C6-alkyl, C1-C6-acyl, C1-C4-alkoxycarbonyl, C1-C4-alkylthiocarbonyl, C1-C6-alkylaminocarbonyl or arylaminocarbonyl group; and R2 is a hydrogen atom or a C1-C6-alkyl or C1-C6-acyl group. Compounds of formula I bind more strongly to the glucocorticoid receptor than to the progesterone receptor and are effective antiglucocorticoids. According to the invention, they are suitable for the treatment and/or prevention of symptoms and/or diseases that are attributable to an androgen deficiency induced by glucocorticoids, especially cortisol.
摘要:
Compounds of general formula I as well as their pharmaceutically compatible salts are described, in which R1 stands for hydrogen, C1- to C6-alkyl, COR4, COOR4, COSR4 or CONHR5, in which R4 is C1- to C6-alkyl or unsubstituted or substituted aryl and in which R5 is hydrogen, C1- to C6-alkyl or unsubstituted or substituted aryl, in which R2 also stands for hydrogen, C1- to C6-alkyl or C1- to C6-acyl, and R3 stands for a CnF2n+1 group, in which n=1, 2 or 3, or a CH2O(CH2)mCnF2n+1 group, in which m=0 or 1 and n=1, 2 or 3. In addition, a process for the production of the compounds with general formula I is indicated. The compounds can be used for the production of pharmaceutical agents.
摘要:
Described are new 14,15-cyclopropano steroids of the 19-norandrostane series of general formula (I) and their pharmaceutically acceptable salts, a process for their production and pharmaceutical preparations that contain these compounds. The compounds are distinguished by hormonal (gestagenic and/or androgenic) activity.
摘要:
The present patent application relates to 11β-benzaldoxime derivatives of D-homooestra-4,9-dien-3-ones of formula I: wherein R1 is a hydrogen atom or a C1-C6-alkyl, C1-C6-acyl, C1-C4-alkoxycarbonyl, C1-C4-alkylthiocarbonyl, C1-C6-alkylaminocarbonyl or arylaminocarbonyl group; and R2 is a hydrogen atom or a C1-C6-alkyl or C1-C6-acyl group. Compounds of formula I bind more strongly to the glucocorticoid receptor than to the progesterone receptor and are effective antiglucocorticoids. According to the invention, they are suitable for the treatment and/or prevention of symptoms and/or diseases that are attributable to an androgen deficiency induced by glucocorticoids, especially cortisol.
摘要:
This invention relates to a process for the production of 4-(17α-alkoxymethyl-17β-substituted-3-oxoestra-4,9-dien-11β-yl)benzaldehyde-(1E)-oxime derivatives of general formula (I) in which R means an amino group, an O—C1-7-alkyl- or O-aryl radical, an S—C1-7-alkyl- or S-aryl radical, an NH—C1-7-alkyl- or NH-aryl radical or an N-di-C1-7-alkyl radical, and R1 means a hydrogen atom or a C1-6-alkyl radical, which yields the target compounds of formula (I) with high yield and selectivity.